ImmuronFRA:ANWA +11.83%56 Days Payable is 148.96 as of Dec. 2025, which is 69% below its 10-year median of 477.87. GuruFocus rates FRA:ANWA with a GF Score™ of 56/100 and a GF Value™ of €6.13 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 699 Biotechnology companies, Immuron ranks better than 59.66% on this metric.
Immuron's average Accounts Payable for the
six
months ended in Dec. 2025 was €0.71 Mil. Immuron's Cost of Goods Sold for the
six
months ended in Dec. 2025 was €0.87 Mil.
Hence, Immuron's Days Payable for the
six
months ended in Dec. 2025 was 148.96.
The historical rank and industry rank for Immuron's Days Payable or its related term are showing as below:
FRA:ANWA'
s Days Payable Range Over the Past 10 Years
Min: 119.83 Med: 477.87 Max: 1200.6
Current: 169.89
During the past 11 years, Immuron's highest Days Payable was 1200.60. The lowest was 119.83. And the median was 477.87.
FRA:ANWA's Days Payable is ranked better than 59.66% of 699
companies
in the Biotechnology industry
Industry Median: 112.84
vs FRA:ANWA: 169.89
Immuron's Days Payable
increased
from Dec. 2024 (132.98) to Dec. 2025 (148.96).
It may suggest that Immurondelayed paying its suppliers.
Immuron Days Payable Related Terms
Immuron Days Payable Historical Data
* Premium members only.
The historical data trend for Immuron's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ANWA vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Immuron's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuron Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuron's Days Payable distribution charts can be found below:
* The bar in red indicates where Immuron's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Immuron's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuron (FRA:ANWA) has a Days Payable of 148.96 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immuron and its competitors. This is 69% below median its historical median of 477.87. Over the past decade, Immuron's Days Payable has ranged from 119.83 to 1,200.60. According to the industry distribution chart, Immuron ranks #282 out of 699 companies in the Biotechnology industry, placing it in the top 40.3%.
Is Immuron's Days Payable too high?
Immuron's current Days Payable of 148.96 is 69% below median its 10-year median of 477.87. Over the past 10 years, this metric has ranged from a low of 119.83 to a high of 1,200.60. The Biotechnology industry median Days Payable is 112.84. Immuron's value of 148.96 is 32% above this industry median. Based on the distribution chart, Immuron ranks #282 out of 699 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immuron has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immuron's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuron ranks #282 out of 699 companies for Days Payable. This puts Immuron in the upper half of its industry. The industry median Days Payable is 112.84. Immuron's value of 148.96 is 32% above this benchmark. Historically, Immuron's own Days Payable has ranged from 119.83 to 1,200.60 over the past decade. While the company's 10-year median is 477.87 vs. the industry median of 112.84, Immuron has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuron's current Days Payable of 148.96 is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immuron and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuron's current Days Payable is 148.96, which is 69% below median its own 10-year median of 477.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuron stock overvalued right now?
Based on GuruFocus' analysis, Immuron (FRA:ANWA) is currently considered Possible Value Trap. The stock's GF Value™ is €6.13, compared to a current price of €1.04 — trading 83% below its estimated fair value. The current Days Payable is 148.96, which is 69% below median its 10-year median of 477.87 and 32% above the Biotechnology industry median of 112.84. Immuron's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Immuron (FRA:ANWA), the current Days Payable is 148.96 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuron (FRA:ANWA) Overvalued in 2026?
Based on GuruFocus' analysis, Immuron stock appears to be undervalued.
The current stock price of €1.04 is trading 83% below its estimated GF Value™ of €6.13.
GuruFocus considers Immuron to be Possible Value Trap.
Key valuation signals for FRA:ANWA:
Days Payable: 148.96 (69% below median its 10-year median of 477.87)
GF Value™: €6.13 vs. price of €1.04 (83% below fair value)
Industry Position: 32% above the Biotechnology median (#282 of 699)
No single metric tells the full story. See the FRA:ANWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
56GF Score
Get the complete analysis for FRA:ANWA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ANWA has been successfully added to your 
